Devinder Gill
About
In The Last Decade
Devinder Gill
142 papers receiving 5.2k citations
Hit Papers
Peers
Comparison fields: 5 of 122
- Pathology and Forensic Medicine 2.7k
- Oncology 2.5k
- Genetics 1.4k
- Immunology 1.2k
- Molecular Biology 946
Countries citing papers authored by Devinder Gill
This map shows the geographic impact of Devinder Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devinder Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devinder Gill more than expected).
Fields of papers citing papers by Devinder Gill
This network shows the impact of papers produced by Devinder Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devinder Gill. The network helps show where Devinder Gill may publish in the future.
Co-authorship network of co-authors of Devinder Gill
This figure shows the co-authorship network connecting the top 25 collaborators of Devinder Gill. A scholar is included among the top collaborators of Devinder Gill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Devinder Gill. Devinder Gill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 9 | |
| 4 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial breakdown → | 380 |
| 5 | 4 | |
| 6 | 13 | |
| 7 | 29 | |
| 8 | 83 | |
| 9 | 49 | |
| 10 | Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era breakdown → | 1117 |
| 11 | 2 | |
| 12 | 139 | |
| 13 | Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients | 1 |
| 14 | 24 | |
| 15 | 52 | |
| 16 | LAG-3 expressing lymphocytes suppress EBV latent membrane protein-specific T cell function in Hodgkins lymphoma patients | 1 |
| 17 | Incidence and nature of CD20 negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review. | 17 |
| 18 | 6 | |
| 19 | Growth and performance of pulsed laser deposited indium oxide thin-film holographic recorders | 6 |
| 20 | 5 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.